17:18 , Apr 25, 2019 |  BC Innovations  |  Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
15:48 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
14:34 , Jun 29, 2018 |  BC Week In Review  |  Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
18:52 , Jun 26, 2018 |  BC Extra  |  Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
22:05 , Apr 25, 2018 |  BC Extra  |  Company News

Management tracks: Urovant, Cue

Urology company Urovant Sciences, a subsidiary of Roivant Sciences GmbH (Basel, Switzerland), hired Cornelia Haag-Molkenteller as CMO, Michael McFadden as chief commercial officer, Bryan Smith as general counsel and Christine Ocampo as SVP and chief...
05:12 , Nov 2, 2017 |  BC Week In Review  |  Company News

Bio-Techne acquires Trevigen

In September, Bio-Techne Corp. (NASDAQ:TECH) acquired fellow supply and service company Trevigen Inc. (Gaithersburg, Md.) for $11 million in cash. Trevigen specializes in reagents, kits and cell cultures to study programmed cell death and DNA...
00:17 , Apr 29, 2017 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
03:06 , Feb 4, 2017 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 10 biotechs and pharmas are expected to report earnings the week of Feb. 6. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q Company Date Pre/post mkt 4Q16 EPS est...
07:00 , Oct 31, 2016 |  BioCentury  |  Finance

Quark’s global ambitions

After getting its toes wet with a couple of biotech seed investments and hiring a drug development veteran as partner and CEO, Canadian VC Quark Venture Inc. teamed up with GF Securities Co. Ltd. (SZSE:000776;...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Advanced Cell Diagnostics, Bio-Techne deal

Research supplier Bio-Techne will acquire Advanced Cell Diagnostics. Advanced Cell Diagnostics will receive $250 million in cash up front and is eligible for up to $75 million in milestones. Bio-Techne expects the deal to close...